CV risk assessment essential for CML TKI trial design By Lynda Williams.

Related StoriesResearchers find that 26 percent of senior oncology individuals use complementary or alternate medicinesLilly expands existing immuno-oncology collaboration with AstraZenecaAMSBIO launches Mimetix 3D cell culture scaffolds for medication discovery, oncology researchWhile a threat of ventricular arrhythmia associated with QT prolongation is not confirmed in sufferers given the second-generation TKI nilotinib, reports have suggested an elevated threat of hyperglycaemia and peripheral arterial disease, including severe events needing invasive therapy or amputation. And AE rates are particularly elevated in sufferers with several of the original atherosclerosis risk factors, such as hypertension and diabetes. Licensed from medwireNews with authorization from Springer Healthcare Ltd.Healthcare system in ’09 2009, We actually want to work together to complete the job . This article is usually republished with kind permission from our close friends at The Kaiser Family Foundation. You will see the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery of in-depth coverage of wellness policy developments, debates and discussions. The Kaiser Daily Health Policy Report is released for Kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation. Copyright 2007 Advisory Board Firm and Kaiser Family Base. All rights reserved.

Chagas disease specifically harmful for pregnant ladies; New, better treatments needed ‘Chagas disease – – a parasitic infection transmitted via an insect commonly known as the ‘kissing bug’ – – is among the most common attacks among pregnant women in the Western Hemisphere,’ Peter Hotez, president of the Sabin Vaccine Institute and director of the Sabin Vaccine Institute and Texas Children’s Hospital Middle for Vaccine Development, writes in the Huffington Post’s ‘Global Motherhood’ blog.